KALV - Company ID 0001348911
The table below shows KalVista Pharmaceuticals, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | $50.00M | - | - | - | $12.69M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $71.71M | $86.17M | $80.28M | $70.17M | $41.29M | $40.19M |
| SG&A |
KalVista Pharmaceuticals, Inc. reported annual revenue of $50.00M for fiscal year 2024. That is up 294.0% from $12.69M in fiscal 2020. Over the 6 fiscal years shown, annual revenue grew from $2.13M (FY 2016) to $50.00M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $116.29M |
| $54.28M |
| $30.59M |
| $26.45M |
| $16.64M |
| $13.03M |
| Operating income | -$188.00M | -$140.44M | -$110.87M | -$96.61M | -$57.92M | -$40.53M |
| Income tax | $3.39M | $0.00 | $0.00 | $0.00 | $0.00 | -$124.00K |
| Net income | -$183.40M | -$126.60M | -$92.90M | -$82.34M | -$46.24M | -$29.12M |
| EPS (diluted) | -$3.69 | -$3.44 | -$3.33 | -$3.36 | -$2.42 | -$1.64 |